RBM42

Across TCGA pan-cancer cohorts, RBM42 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBM42 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RBM42 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBM42 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where RBM42 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.904	0.465	.002	21	view →
COAD	DFS	Median	All	1.000	0.888	.023	12	view →
LUAD	DFS	Tertile	III,IV	0.732	1.000	.038	6	view →
GBM	OS	Quartile	All	0.578	0.293	.014	3	view →
LSCC	DFS	Tertile	III,IV	0.795	1.000	.036	3	view →
PDAC	DFS	Median	III,IV	0.512	0.200	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBM42–CCRCC (DFS)

Open the CCRCC breakdown →